The impact of PBRM1 mutation on immunotherapy response remains difficult to understand: a recent pan-cancer analysis of 168 PBRM1-mutated tumors vs. 1743 nonmutated tumors revealed that in ccRCC the PRBM1 mutation has no association with immunotherapy response or immune-related biomarkers, while in other cancer types (endometrial carcinoma, stomach adenocarcinoma, and colon adenocarcinoma) this mutation is significantly associated with immune-related biomarkers [39]. The gene discussed is PBRM1; the disease is gastric adenocarcinoma.